成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ABT-089

ABT-089 Struktur
161417-13-6
CAS-Nr.
161417-13-6
Englisch Name:
ABT-089
Synonyma:
(S)-3-(Azetidin-2-ylmethoxy)-2-methylpyridine;Pyridine, 3-[(2S)-2-azetidinylmethoxy]-2-methyl-;3-[[(2S)-azetidin-2-yl]methoxy]-2-methylpyridine
CBNumber:
CB52627246
Summenformel:
C10H14N2O
Molgewicht:
178.23
MOL-Datei:
161417-13-6.mol

ABT-089 Eigenschaften

Sicherheit

ABT-089 Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride salt] is a selective neuronal nicotinic receptor (NNR) modulator with cognitive enhancing properties in animal models of cognitive functioning. Amongst NNR subtypes, ABT-089 shows selectivity for the cytisine binding site on the alpha4beta2 receptor subtype as compared to the alpha-bungarotoxin (alpha-BgT) binding sites on the alpha7 and alpha1beta1deltagamma receptor subtypes. In functional in vitro electrophysiological and cation flux assays, ABT-089 displays differential activity including agonism, partial agonism and antagonism depending upon the NNR subtype and assay. ABT-089 is as potent and efficacious as (-)-nicotine at evoking acetylcholine (ACh) release from hippocampal synaptosomes. Furthermore, ABT-089 is neuroprotective against excitotoxic glutamate insults, with even greater potency seen after chronic treatment. Similarly, ABT-089 is effective in models of cognitive functioning, including enhancement of baseline functioning as well as improvement of impaired cognitive functioning seen following septal lesioning and natural aging. In neuroprotective assays the compound is most potent by chronic administration. In stark contrast to the positive effects in the cognitive models, ABT-089 shows little propensity to induce adverse effects such as ataxia, hypothermia, seizures, cardiovascular or gastrointestinal side effects. Together these data suggest that ABT-089 is a NNR modulator with the potential for treating cognitive disorders with markedly limited adverse cardiovascular and gastrointestinal side effects.

Einzelnachweise

[1] LYNNE E. RUETER. ABT-089: Pharmacological Properties of a Neuronal Nicotinic Acetylcholine Receptor Agonist for the Potential Treatment of Cognitive Disorders[J]. CNS drug reviews, 2006, 10 2: 167-182. DOI:10.1111/j.1527-3458.2004.tb00011.x.
[2] ARNERIC S, BANNON A, BRIONI J, et al. ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action[C]. 1900: 0. DOI:10.1007/978-1-4612-4116-4_42.

ABT-089 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


ABT-089 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 3)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Chengdu Feibo Pharm Technology Co., Ltd +86 028-84641798 15982321820
abby@arkpharm.com China 10923 58
Jinan Mingya Medical Technology Co., Ltd. 0531-85828981
864598798@qq.com China 588 58
JinOu Biomedical (Nanjing) Co., Ltd. 13000000000
jinoupharma@163.com China 11721 58

  • 3-[[(2S)-azetidin-2-yl]methoxy]-2-methylpyridine
  • (S)-3-(Azetidin-2-ylmethoxy)-2-methylpyridine
  • Pyridine, 3-[(2S)-2-azetidinylmethoxy]-2-methyl-
  • 161417-13-6
Copyright 2019 ? ChemicalBook. All rights reserved